Category Archives: Dr. Lucey COVID-19 Origins

Comments on key documents from the early weeks of SARS-CoV-2

By on .

By Daniel R. Lucey MD, MPH, FIDSA The purpose of this blog is to provide comments on reporting of some of the key COVID-19 events from 23 Chinese publications dated Dec. 31, 2019, until Feb. 17, 2021. Except for the five from the China CDC Weekly website, most are no longer online; however, I saved […]

Clues to COVID origins via Wuhan wet market study 2017-2019 of severe fever with thrombocytopenia syndrome

By on .

By Daniel R. Lucey MD, MPH, FIDSA Retrospective testing for SARS-CoV-2 virus and antibody could be (or has been) done using blood and other samples highly likely to have been obtained from the 18 mammalian species (including masked palm civet, racoon dogs, and mink) reported in the Wuhan wet markets, May 2017-November 2019, as part […]

Not until June 2021 does China report Wuhan wet markets sold palm civets, racoon dogs and mink from 2017-2019: Where are the SARS-CoV-2 results?

By on .

By Daniel R. Lucey MD, MPH, FIDSA Last month a paper titled “Animal sales from Wuhan wet markets immediately prior to the COVID-19 pandemic” by Xiao et al., in Nature Scientific Reports listed 18 mammalian species sold May 2017 -November 2019 in Wuhan wet markets (Table 1).  These mammalian species included masked palm civets (Paguma […]

Will the China report on 266 patients Nov. 17-Dec. 31, 2019 be made public by China, WHO, or by WHA resolution next week?

By on .

By Daniel R. Lucey MD, MPH, FIDSA In a recent Science paper by Pekar, Worobey and colleagues titled “Timing the SARS-CoV-2 index case in Hubei province” the authors conclude “Our results define the period between mid-October and mid-November 2019 as the plausible interval when the first case of SARS-CoV-2 emerged in Hubei province.” Referencing reporting […]

Four problems with the lab origin hypothesis of SARS-CoV-2 and the WHO-China study

By on .

By Daniel R. Lucey MD, MPH, FIDSA Today the Joint WHO-China Study 14 January-10 February 2021 for the “WHO-convened Global Study of origins of SARS-CoV-2: China Part” was posted on the World Health Organization’s website.  Zero patients with COVID were reported before December 8, 2021, yet 174 patients were found between Dec. 8 to 31, […]

Will the next “WHO-convened Global Study of the origins of SARS-CoV-2” be in SE Asia, Europe, or the Americas?

By on .

By Daniel R. Lucey MD, MPH, FIDSA By July 31, 2020 the World Health Organization and China had agreed in writing to a highly-consequential document with long-term implications titled “WHO-convened Global Study of the Origins of SARS-CoV-2: Terms of References for the China Part”. This title, as well as multiple statements in the text such […]

Why did the WHO-China team call the lab origin hypothesis “extremely unlikely” when their “Terms of References” did not mention it at all?

By on .

By Daniel R. Lucey MD, MPH, FIDSA Following the May 2020 World Health Assembly resolution 73.1 regarding COVID-19 (item 6 on page 6), the World Health Organization and China agreed in writing in a July 31 July 2020 document titled “WHO-convened Global Study of the Origins of SARS-CoV-2 ‘Terms of References for the China Part‘”. […]

FDA-USDA statement timely in light of imminent WHO-China COVID-19 team summary

By on .

By Daniel R. Lucey MD, MPH, FIDSA Today this statement (also provided below) from the United States Food and Drug Administration, acting Commissioner Janet Woodcock M.D., and US Department of Agriculture acting Secretary Kevin Shea concluded that there is currently no scientific or epidemiologic basis for the claim that SARS-CoV-2/COVID-19 is transmitted via food or […]

Advances since 2001 include FDA-approved anthrax antitoxins available now

By on .

With most eyes on COVID-19, it would be prudent to remain vigilant for older threats at the same time By Daniel R. Lucey MD, MPH, FIDSA A major difference in treatment and prophylaxis for inhalational anthrax since the attacks of 2001 is the availability of three U.S. Food and Drug Administration approved antitoxins. Several key […]

Five questions on new data from China-WHO showing 124 confirmed coronavirus patients in December 2019

By on .

By Daniel R. Lucey M.D., MPH, FIDSA After China initially reported 41, then ~ 46, and then ~ 100 laboratory-confirmed cases in December 2019, a total of 124 confirmed cases in December was reported by China July 31 but for some reason only posted on the WHO website Nov. 5. First posted on the WHO […]